Company: BGLC
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001477932-25-003821
Chunk: 2

Company: BioNexus Gene Lab Corp
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
 )  (3,442,620 )Accumulated other comprehensive losses      (482,841 )  (555,000 )TOTAL STOCKHOLDERS’ EQUITY      7,771,636   8,322,804              TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY     $9,479,939  $10,433,848 

* Issued and outstanding shares of common stock have been adjusted for the periods prior to July 20, 2023, to reflect the 12-for-1 reverse stock split effected on that date on a retroactive basis as described in Note 12.

See accompanying notes to the consolidated financial statements.

 5Table of Contents

BIONEXUS GENE LAB CORP.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME/(LOSS) 

FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

  Three months ended March 31,  2025  2024        REVENUE (including $16,070 and $34,086 of revenue from related parties for the period ended March 31, 2025 and 2024 respectively) $2,137,075  $2,381,851          COST OF REVENUE (including $nil and $77,214 of cost of revenue from related parties for the periods ended March 31, 2025 and 2024, respectively)  (1,793,582)  (2,016,820)         GROSS PROFIT  343,493   365,031          OTHER INCOME        Dividend income  8,934   8,946 Interest income  23,568   28,983 Fair value gain on investments in equity securities  4,514   84,785 Gain on disposal of investments in equity securities  -   6,181 Reversal of expected credit losses  25,153   31,752 Others  29,251   41,200 TOTAL OTHER INCOME  91,420   201,847          OPERATING EXPENSES        Sales and marketing  (540,695)  (